Rohto Pharmaceutical Co(MX:4527N)
MX$290.000.00 (0.00%)
MX:4527N
Rohto Pharmaceutical Co financials statements
MX$290.00
At close:0.00 (0.00%)
Rohto Pharmaceutical Co (4527N) Ratios
0 Followers
Rohto Pharmaceutical Co Ratios
MX:4527N's free cash flow for Q2 2026 was ¥0.00. For the 2026 fiscal year, MX:4527N's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.30 | 2.04 | 2.47 | 2.37 | 2.30 |
| Quick Ratio | 1.65 | 1.48 | 1.93 | 1.86 | 1.83 |
| Cash Ratio | 0.82 | 0.74 | 1.02 | 1.00 | 1.02 |
| Solvency Ratio | 0.29 | 0.31 | 0.40 | 0.36 | 0.32 |
| Operating Cash Flow Ratio | 0.39 | 0.41 | 0.39 | 0.39 | 0.38 |
| Short-Term Operating Cash Flow Coverage | 3.40 | 1.93 | 6.46 | 7.40 | 3.39 |
| Net Current Asset Value | ¥ 67.45B | ¥ 73.68B | ¥ 115.62B | ¥ 95.64B | ¥ 73.51B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.12 | 0.03 | 0.04 | 0.08 |
| Debt-to-Equity Ratio | 0.24 | 0.20 | 0.04 | 0.06 | 0.12 |
| Debt-to-Capital Ratio | 0.19 | 0.17 | 0.04 | 0.05 | 0.11 |
| Long-Term Debt-to-Capital Ratio | 0.14 | 0.09 | 0.02 | 0.03 | 0.07 |
| Financial Leverage Ratio | 1.62 | 1.61 | 1.41 | 1.48 | 1.54 |
| Debt Service Coverage Ratio | 3.81 | 2.04 | 7.32 | 7.79 | 3.52 |
| Interest Coverage Ratio | 40.53 | 31.70 | 204.33 | 137.49 | 118.34 |
| Debt to Market Cap | 0.11 | 0.10 | 0.02 | 0.02 | 0.05 |
| Interest Debt Per Share | 272.96 | 272.29 | 46.86 | 52.34 | 94.81 |
| Net Debt to EBITDA | -0.28 | -0.41 | -1.56 | -1.61 | -1.44 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.91% | 53.23% | 58.07% | 57.58% | 58.35% |
| EBIT Margin | 14.02% | 14.00% | 15.40% | 14.47% | 14.09% |
| EBITDA Margin | 18.28% | 19.05% | 18.61% | 17.74% | 17.94% |
| Operating Profit Margin | 12.46% | 11.84% | 14.79% | 14.23% | 14.70% |
| Pretax Profit Margin | 13.72% | 13.62% | 15.33% | 14.37% | 14.00% |
| Net Profit Margin | 10.05% | 9.96% | 11.42% | 11.05% | 10.58% |
| Continuous Operations Profit Margin | 10.03% | 10.01% | 11.59% | 11.07% | 10.61% |
| Net Income Per EBT | 73.24% | 73.15% | 74.51% | 76.92% | 75.58% |
| EBT Per EBIT | 110.05% | 115.02% | 103.67% | 100.97% | 95.24% |
| Return on Assets (ROA) | 7.35% | 7.05% | 8.94% | 8.52% | 7.69% |
| Return on Equity (ROE) | 11.92% | 11.35% | 12.56% | 12.59% | 11.85% |
| Return on Capital Employed (ROCE) | 11.75% | 11.05% | 15.46% | 14.80% | 14.45% |
| Return on Invested Capital (ROIC) | 8.32% | 7.61% | 11.45% | 11.20% | 10.57% |
| Return on Tangible Assets | 8.48% | 8.52% | 9.18% | 8.79% | 7.96% |
| Earnings Yield | 6.09% | 6.30% | 4.51% | 4.17% | 5.01% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.42 | 4.47 | 3.92 | 3.93 | 3.86 |
| Payables Turnover | 6.31 | 7.10 | 5.38 | 5.41 | 5.11 |
| Inventory Turnover | 2.26 | 2.45 | 2.43 | 2.47 | 2.48 |
| Fixed Asset Turnover | 3.41 | 3.70 | 3.95 | 3.61 | 3.18 |
| Asset Turnover | 0.73 | 0.71 | 0.78 | 0.77 | 0.73 |
| Working Capital Turnover Ratio | 2.46 | 2.80 | 2.28 | 2.35 | 2.36 |
| Cash Conversion Cycle | 186.31 | 179.30 | 175.22 | 173.32 | 170.24 |
| Days of Sales Outstanding | 82.64 | 81.60 | 93.14 | 92.76 | 94.49 |
| Days of Inventory Outstanding | 161.52 | 149.11 | 149.97 | 148.04 | 147.16 |
| Days of Payables Outstanding | 57.85 | 51.41 | 67.90 | 67.48 | 71.41 |
| Operating Cycle | 244.16 | 230.71 | 243.11 | 240.80 | 241.65 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 162.06 | 211.49 | 150.11 | 135.55 | 119.44 |
| Free Cash Flow Per Share | 122.20 | 160.62 | 111.04 | 92.12 | 69.79 |
| Dividend Paid and CapEx Coverage Ratio | 2.29 | 2.30 | 2.38 | 2.12 | 1.85 |
| Capital Expenditure Coverage Ratio | 4.07 | 4.16 | 3.84 | 3.12 | 2.41 |
| Operating Cash Flow Coverage Ratio | 0.60 | 0.79 | 3.26 | 2.64 | 1.27 |
| Operating Cash Flow to Sales Ratio | 0.12 | 0.14 | 0.13 | 0.13 | 0.14 |
| Free Cash Flow Yield | 5.46% | 6.67% | 3.70% | 3.33% | 3.78% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 16.43 | 15.88 | 22.15 | 23.96 | 19.95 |
| Price-to-Sales (P/S) Ratio | 1.65 | 1.58 | 2.53 | 2.65 | 2.11 |
| Price-to-Book (P/B) Ratio | 1.96 | 1.80 | 2.78 | 3.02 | 2.36 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 18.30 | 14.99 | 27.05 | 30.07 | 26.47 |
| Price-to-Operating Cash Flow Ratio | 13.80 | 11.38 | 20.01 | 20.44 | 15.47 |
| Price-to-Earnings Growth (PEG) Ratio | 43.69 | 1.40 | 1.28 | 0.96 | 0.76 |
| Enterprise Value Multiple | 8.75 | 7.90 | 12.04 | 13.31 | 10.33 |
| Enterprise Value | 493.56B | 517.44B | 606.61B | 563.69B | 370.08B |
| EV to EBITDA | 8.75 | 7.90 | 12.04 | 13.31 | 10.33 |
| EV to Sales | 1.60 | 1.51 | 2.24 | 2.36 | 1.85 |
| EV to Free Cash Flow | 17.73 | 14.26 | 23.95 | 26.82 | 23.24 |
| EV to Operating Cash Flow | 13.37 | 10.83 | 17.71 | 18.23 | 13.58 |
| Tangible Book Value Per Share | 945.43 | 1045.65 | 1042.42 | 900.83 | 765.04 |
| Shareholders’ Equity Per Share | 1141.75 | 1335.73 | 1079.71 | 918.60 | 781.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.27 | 0.26 | 0.24 | 0.23 | 0.24 |
| Revenue Per Share | 1354.78 | 1521.15 | 1187.18 | 1046.13 | 875.10 |
| Net Income Per Share | 136.10 | 151.56 | 135.60 | 115.62 | 92.61 |
| Tax Burden | 0.73 | 0.73 | 0.75 | 0.77 | 0.76 |
| Interest Burden | 0.98 | 0.97 | 1.00 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.05 | 0.04 | 0.04 | 0.05 | 0.04 |
| SG&A to Revenue | 0.38 | 0.37 | 0.17 | 0.18 | 0.20 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.19 | 1.40 | 1.11 | 0.90 | 0.97 |
Currency in JPY
